Levoxyl 25 ug tablet

Where the pills inside were made

This label doesn't name the factory that makes the drug. Companies don't have to print it on the label. The maker's name is often on the stock bottle your pharmacy used; you can ask the pharmacist. See the plants Pfizer Laboratories Div Pfizer Inc names for other drugs.

Repackaging site

• Physicians Total Care, Inc., Tulsa, Oklahoma, United States · repackages it and relabels it

Recalls

• Sep 29, 2026 · Class II · Pfizer
  Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
  Lots: Lot # 24W07, Exp: 11/30/2026
• Sep 29, 2026 · Class II · Pfizer
  Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
  Lots: Lot # 24W06, Exp: 11/30/2026
• Jul 29, 2025 · Class II · Pfizer
  Subpotent drug
  Lots: Lot #: 24C11, Exp 2/28/2026.
• Mar 15, 2021 · Class II · Cardinal Health Inc.
  CGMP Deviations: Intermittent exposure to temperature excursion during storage.
  Lots: 20D27
• Dec 6, 2018 · Class II · Pfizer Inc.
  Superpotent Drug.
  Lots: Lot #:18A18, Exp. 01/2020
• Nov 7, 2016 · Class II · Pfizer Inc.
  Superpotent
  Lots: 16H21, Exp. 08/2017
• Apr 30, 2013 · Class II · King Legacy, a wholly owned subsidiary of Pfizer
  Subpotent Drug: The products were below specification for potency at the expiry stability point.
  Lots: Lot # a) 65228, Exp. 06/13; 65636, Exp. 08/13; b) 65180, Exp. 05/13; 65769, Exp. 07/13
• Apr 30, 2013 · Class II · King Legacy, a wholly owned subsidiary of Pfizer
  Subpotent Drug: The products were below specification for potency at the expiry stability point.
  Lots: Lot # a) 64934, Exp. 4/13; 65059, Exp. 5/13; 65179, Exp. 4/13; 65630, Exp. 7/13; 65916, Exp. 8/13; 66367, Exp. 10/13; and 66718, Exp. 11/13; b) 64338, Exp. 4/13; 64932, Exp. 4/13; 65060, Exp. 5/13; 65235, Exp. 6/13; 65853, Exp. 6/13; and 65962, Exp. 7/13
• Apr 30, 2013 · Class II · King Legacy, a wholly owned subsidiary of Pfizer
  Subpotent Drug: The products were below specification for potency at the expiry stability point.
  Lots: Lot # a) 64197, Exp. 4/13; 64339, Exp. 4/13; 65061, Exp. 5/13; 65236, Exp. 6/13; 65917, Exp. 8/13; 66122, Exp. 8/13; and 66427, Exp. 9/13; b) 64340, Exp. 4/13; 64933, Exp. 4/13; 65062, Exp. 5/13; 65237, Exp. 6/13; 65238, Exp. 6/13; and 66121, Exp. 8/13
• Apr 30, 2013 · Class II · King Legacy, a wholly owned subsidiary of Pfizer
  Subpotent Drug: The products were below specification for potency at the expiry stability point.
  Lots: Lot # a) 64935, Exp. 5/13; 65239, Exp. 6/13; 65900, Exp. 8/13; 66370, Exp. 10/13; and 66391, Exp. 9/13; b) 64927, Exp. 5/13; and 65240, Exp. 6/13
• Apr 30, 2013 · Class II · King Legacy, a wholly owned subsidiary of Pfizer
  Subpotent Drug: The products were below specification for potency at the expiry stability point.
  Lots: Lot # a) 64341, Exp 04/13; 64928, Exp. 5/13; 65064, Exp. 5/13; 65233, Exp. 7/13; 66162, Exp. 8/13; 66365, Exp. 10/13; and 66677, Exp. 11/13; b) 64342, Exp. 4/13; 64929, Exp. 5/13; 65065, Exp. 5/13; 65234, Exp. 7/13; 65539, Exp. 7/13; 65901, Exp. 8/13; and 66163, Exp. 8/13
• Apr 30, 2013 · Class II · King Legacy, a wholly owned subsidiary of Pfizer
  Subpotent Drug: The products were below specification for potency at the expiry stability point.
  Lots: Lot # a) 64936, Exp. 5/13; 65634, Exp. 7/13; 66295, Exp. 9/13; 66669, Exp. 11/13; b) 65063, Exp. 5/13 and 65767, Exp. 7/13
• Apr 30, 2013 · Class II · King Legacy, a wholly owned subsidiary of Pfizer
  Subpotent Drug: The products were below specification for potency at the expiry stability point.
  Lots: Lot # a) 64333, Exp. 5/13; 64937, Exp. 6/13; 65629, Exp. 7/13; and 66296, Exp. 9/13; b) 64931, Exp. 5/13 and 65766, Exp. 7/13
• Apr 30, 2013 · Class II · King Legacy, a wholly owned subsidiary of Pfizer
  Subpotent Drug: The products were below specification for potency at the expiry stability point.
  Lots: Lot # a) 64190, Exp. 4/13; 64331, Exp. 6/13; 65642, Exp. 7/13; and 66297, Exp. 9/13; b) 64326, Exp. 4/13; 64332, Exp. 6/13; and 65771, Exp. 7/13
• Apr 30, 2013 · Class II · King Legacy, a wholly owned subsidiary of Pfizer
  Subpotent Drug: The products were below specification for potency at the expiry stability point.
  Lots: Lot # a) 65066, Exp. 5/13 and 65644, Exp. 7/13; b) 64327, Exp. 4/13 and 65772, Exp. 7/13
• Apr 30, 2013 · Class II · King Legacy, a wholly owned subsidiary of Pfizer
  Subpotent Drug: The products were below specification for potency at the expiry stability point.
  Lots: Lot # a) 64329, Exp. 5/13; 65229, Exp. 6/13; and 65913, Exp. 9/13; b) 64330, Exp. 5/13; 65230, Exp. 6/13; and 65915, Exp. 9/13
• Apr 30, 2013 · Class II · King Legacy, a wholly owned subsidiary of Pfizer
  Subpotent Drug: The products were below specification for potency at the expiry stability point.
  Lots: Lot # a) 64301, Exp. 4/13 and 65628, Exp. 7/13; b) 64300, Exp. 4/13 and 65765, Exp. 7/13
• Mar 28, 2013 · Class II · Pfizer Inc.
  Chemical contamination: emission of strong odor after package was opened..
  Lots: Lot # a) 66675B, Exp. 10/13; b) 66852B Exp. 10/13; 67138B, Exp. 02/14
• Mar 28, 2013 · Class II · Pfizer Inc.
  Chemical contamination: emission of strong odor after package was opened.
  Lots: Lot # a) 66730B, 66853B, Exp. 01/14; b) 66731B, 67116B, Exp. 11/13, 66856B, Exp. 12/13; 67341B, Exp, 02/14
• Mar 28, 2013 · Class II · Pfizer Inc.
  Chemical contamination: emission of strong odor after package was opened.
  Lots: Lot # a) 66369B, Exp. 10/13; 66679B, Exp. 11/13; 66850B, Exp. 12/13; b) 66676B, 66732B, Exp. 12/13; 67136B, Exp. 03/14
• Mar 28, 2013 · Class II · Pfizer Inc.
  Chemical contamination: emission of strong odor after package was opened..
  Lots: Lot # a) 66619B, Exp. 11/13; 67010B, Exp. 01/14; b) 66733B, Exp. 11/13; 67441B, Exp. 01/14
• Mar 28, 2013 · Class II · Pfizer Inc.
  Chemical contamination: emission of strong odor after package was opened..
  Lots: Lot # a) 66897B, Exp. 12/13; b) 67137B, Exp.02/14
• Mar 28, 2013 · Class II · Pfizer Inc.
  Chemical contamination: emission of strong odor after package was opened.
  Lots: Lot # a) 67343B, Exp. 01/14; b) 66902B, Exp. 12/13
• Mar 28, 2013 · Class II · Pfizer Inc.
  Chemical contamination: emission of strong odor after package was opened
  Lots: Lot # a) 66373B, Exp. 10/13; 66851B, Exp. 12/13; b)66792B, Exp. 12/13; 67349B, Exp. 03/14
• Mar 28, 2013 · Class II · Pfizer Inc.
  Chemical contamination: emission of strong odor after package was opened.
  Lots: Lot # a) 67013B, Exp. 01/14; b) 66900B, Exp. 01/14
• Mar 28, 2013 · Class II · Pfizer Inc.
  Chemical contamination: emission of strong odor after package was opened.
  Lots: Lot # a) 66375B, Exp. 10/13; 66719B, Exp. 01/14; b) 66904B, Exp. 01/14
• Mar 28, 2013 · Class II · Pfizer Inc.
  Chemical contamination: emission of strong odor after package was opened.
  Lots: Lot # a) 67507B, Exp. 02/14; b) 67508B, Exp. 02/14
• Mar 28, 2013 · Class II · Pfizer Inc.
  Chemical contamination: emission of strong odor after package was opened.
  Lots: Lot # a) 66671B, Exp. 11/13; 67512B, Exp. 02/14 b) 66739B Exp. 11/13; 67513B Exp. 02/14

Class I recalls are the most serious; Class III the least. A recall covers specific lots, listed on each recall.

Product details

Generic drug

Levothyroxine: every company that makes it

Form

tablet

Strength

25 ug

Approval

NDA NDA021301

On the market since

Jun 20, 2003

Package NDCs

54868-4087-1

Official label

DailyMed (National Library of Medicine), updated Aug 19, 2013

Got it by mail or from a pharmacy you don't know? Look the pharmacy up on Who Filled My Rx?